Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 9/20 | 0.69 |
| ▸ | NOS3 | P29474 | 2/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 3/20 | 0.32 |
| ▸ | MAOB | P27338 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4073906 | 0.93 | NISCH (0.73) | NISCHNOS3NOS1NOS2CYP2D6 | |
| SCHEMBL19348515 | 0.91 | — | — | |
| SCHEMBL10854575 | 0.89 | NISCH (0.73) | NISCHNOS3NOS1NOS2CYP2D6 | |
| SCHEMBL10852808 | 0.87 | NISCH (0.77) | NISCHNOS3NOS1NOS2CYP2D6 | |
| SCHEMBL11132739 | 0.84 | NISCH (0.87) | NISCHCYP2D6HTR1AADRA2AADRA1A | |
| SCHEMBL21391659 | 0.84 | NISCH (0.95) | NISCHCYP2D6HTR1AADRA2AADRA1A | |
| SCHEMBL11132717 | 0.82 | NISCH (0.83) | NISCHCYP2D6HTR1AADRA2AADRA1A | |
| SCHEMBL1139763 | 0.82 | NISCH (1.00) | NISCHCYP2D6HTR1AADRA2AADRA1A | |
| SCHEMBL8142116 | 0.82 | NISCH (1.00) | NISCHCYP2D6HTR1AADRA2AADRA1A | |
| SCHEMBL11130232 | 0.82 | NISCH (0.91) | NISCHCYP2D6HTR1AADRA2AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6881854-B2 | Conjugated unsaturated glyceride mixtures and a method for producing the same | BASF AKTIENGESELLSCHAFT (DE) | 2005-04-19 | — | — | US | claimed |
| US-20040116738-A1 | Conjugated unsaturated glyceride mixtures and a method for producing the same | BASF AKTIENGESELLSCHAFT (DE) | 2004-06-17 | — | — | US | claimed |
| EP-3686182-A1 | CHEMICALLY ACTIVATED WATER-SOLUBLE PRODRUG | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2020-07-29 | — | — | EP | disclosed |
| US-20200207782-A1 | CHEMICALLY ACTIVATED WATER-SOLUBLE PRODRUG | SUMITOMO DAINIPPON PHARMA CO., LTD (JP) | 2020-07-02 | — | — | US | disclosed |
| CN-111295368-A | Chemically activated water soluble prodrugs | 大日本住友制药株式会社 | 2020-06-16 | — | — | CN | disclosed |
| US-10197557-B2 | Small molecules for endothelial cell activation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-02-05 | — | — | US | disclosed |
| WO-2017011531-A2 | ORGANIC LIGHT-EMITTING DIODE MATERIALS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-01-19 | — | — | WO | disclosed |
| EP-2963039-A1 | SMALL MOLECULES FOR ENDOTHELIAL CELL ACTIVATION | The Regents of The University of California (US) | 2016-01-06 | — | — | EP | disclosed |
| US-8969498-B2 | Compositions and method of inhibiting polymerization of vinyl-aryl monomers | DOW GLOBAL TECHNOLOGIES LLC (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969498-B2 | Compositions and method of inhibiting polymerization of vinyl-aryl monomers | DOW GLOBAL TECHNOLOGIES LLC (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969498-B2 | Compositions and method of inhibiting polymerization of vinyl-aryl monomers | DOW GLOBAL TECHNOLOGIES LLC (US) | 2015-03-03 | — | — | US | disclosed |
| US-6956042-B2 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TARGACEPT, INC. (US) | 2005-10-18 | — | — | US | disclosed |
| US-20050118208-A1 | Powder formulation comprising conjugated octadecapolyenic acids | BASF AKTIENGESELLSCHAFT (DE) | 2005-06-02 | — | — | US | disclosed |
| US-6881854-B2 | Conjugated unsaturated glyceride mixtures and a method for producing the same | BASF AKTIENGESELLSCHAFT (DE) | 2005-04-19 | — | — | US | disclosed |
| EP-1519939-A2 | N-ARYL DIAZASPIRACYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | Targacept, Inc. (US) | 2005-04-06 | — | — | EP | disclosed |
| US-20040116738-A1 | Conjugated unsaturated glyceride mixtures and a method for producing the same | BASF AKTIENGESELLSCHAFT (DE) | 2004-06-17 | — | — | US | disclosed |
| US-20040067930-A1 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TARGACEPT, INC. | 2004-04-08 | — | — | US | disclosed |
| WO-2004005293-A2 | N-ARYL DIAZASPIRACYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| US-5700941-A | Octahydronaphthyridine derivatives | MERCK, SHARP & DOHME, LTD. (GB) | 1997-12-23 | — | — | US | disclosed |
| US-5700941-A | Octahydronaphthyridine derivatives | MERCK, SHARP & DOHME, LTD. (GB) | 1997-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207782-A1 | CHEMICALLY ACTIVATED WATER-SOLUBLE PRODRUG | NR0B1, CYP4A11, CYP4B1 | NISCH 3395/4885NOS3 65/4885NOS1 21/4885 |
| US-10197557-B2 | Small molecules for endothelial cell activation | LIPG, VCAM1, SELE | NISCH 4390/4885NOS3 258/4885NOS1 710/4885 |
| US-20050118208-A1 | Powder formulation comprising conjugated octadecapolyenic acids | ELOVL5, ELOVL6, ELOVL3 | NISCH 497/4885NOS3 2751/4885NOS1 3593/4885 |
| US-20040067930-A1 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TNNC1, ACHE, CHRNA6 | NISCH 92/4885NOS3 820/4885NOS1 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.